Stocktoria
Sanofi SAN.PA
FR · Euronext Paris · XPAR · stock · Healthcare · website
Sanofi financials (annual, from 10-K)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $46.7B | $44.3B | $41.6B | $40.6B |
| Gross profit | $33.7B | $31.1B | $29.0B | $28.7B |
| R&D expense | $7.8B | $7.4B | $6.5B | $6.5B |
| SG&A expense | $10.2B | $9.8B | $9.5B | $8.7B |
| Operating income | $9.6B | $8.9B | $8.7B | $10.9B |
| Interest expense | $626.0M | $704.0M | $643.0M | $465.0M |
| Income tax | $1.0B | $1.2B | $1.0B | $1.9B |
| Net income | $7.8B | $5.6B | $5.4B | $8.4B |
| EPS (diluted) | $6.40 | $4.59 | $4.31 | $5.37 |
| Operating cash flow | $10.8B | $9.1B | $10.3B | $10.5B |
| Free cash flow | $7.2B | $5.9B | $7.4B | $8.4B |
| Cash & equivalents | $7.7B | $7.4B | $8.7B | $12.7B |
| Inventory | $10.2B | $9.4B | $9.7B | $9.0B |
| Total assets | $126.8B | $132.8B | $126.5B | $126.7B |
| Total liabilities | $55.1B | $54.9B | $52.1B | $51.6B |
| Shareholders' equity | $71.4B | $77.5B | $74.0B | $74.8B |
Growth · year-over-year · Revenue CAGR 4.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +5.5% | +6.4% | +2.6% | — |
| Net income growth | +40.5% | +3.0% | -35.5% | — |
| EPS growth | +39.4% | +6.5% | -19.7% | — |
| Free cash flow growth | +22.5% | -19.9% | -12.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · FR · as of 2025-12-31. Figures in EUR; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.